TY - JOUR
T1 - Early detection of pancreatic cancer
T2 - Current state and future opportunities
AU - Trikudanathan, Guru
AU - Lou, Emil
AU - Maitra, Anirban
AU - Majumder, Shounak
N1 - Funding Information:
The current study is financially supported and sponsored by the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (grant NIH DK108288). A.M. is supported by the Khalifa Bin Zayed Al-Nahyan Foundation, and the National Institutes of Health (NIH U01CA196403, U01CA200468, and P50CA221707).
Funding Information:
G.T. serves as a consultant for Boston Scientific Corporation. Mayo Clinic and Exact Sciences Corporation (Madison, WI) own intellectual property under which S.M. is listed as an inventor and could share future royalties paid to Mayo Clinic. A.M. receives royalties for a pancreatic cancer biomarker test from Cosmos Wisdom Biotechnology, and this financial relationship is managed and monitored by the UTMDACC Conflict of Interest Committee. A.M. is also listed as an inventor on a patent that has been licensed by Johns Hopkins University to Thrive Earlier Detection. E.L. reports research grants from the American Association for Cancer Research (2019 AACR-Novocure Tumor-Treating Fields Research Grant, grant number 1-60-62-LOU).
Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Purpose of reviewPancreatic ductal adenocarcinoma (PDAC) is third leading cause of cancer death in the United States, a lethal disease with no screening strategy. Although diagnosis at an early stage is associated with improved survival, clinical detection of PDAC is typically at an advanced symptomatic stage when best in class therapies have limited impact on survival.Recent findingsIn recent years this status quo has been challenged by the identification of novel risk factors, molecular markers of early-stage disease and innovations in pancreatic imaging. There is now expert consensus that screening may be pursued in a cohort of individuals with increased likelihood of developing PDAC based on genetic and familial risk.SummaryThe current review summarizes the known risk factors of PDAC, current knowledge and recent observations pertinent to early detection of PDAC in these risk groups and outlines future approaches that will potentially advance the field.
AB - Purpose of reviewPancreatic ductal adenocarcinoma (PDAC) is third leading cause of cancer death in the United States, a lethal disease with no screening strategy. Although diagnosis at an early stage is associated with improved survival, clinical detection of PDAC is typically at an advanced symptomatic stage when best in class therapies have limited impact on survival.Recent findingsIn recent years this status quo has been challenged by the identification of novel risk factors, molecular markers of early-stage disease and innovations in pancreatic imaging. There is now expert consensus that screening may be pursued in a cohort of individuals with increased likelihood of developing PDAC based on genetic and familial risk.SummaryThe current review summarizes the known risk factors of PDAC, current knowledge and recent observations pertinent to early detection of PDAC in these risk groups and outlines future approaches that will potentially advance the field.
KW - early detection
KW - pancreatic adenocarcinoma
KW - pancreatic cancer screening
KW - pancreatic ductal adenocarcinoma
UR - http://www.scopus.com/inward/record.url?scp=85114089445&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114089445&partnerID=8YFLogxK
U2 - 10.1097/MOG.0000000000000770
DO - 10.1097/MOG.0000000000000770
M3 - Review article
C2 - 34387255
AN - SCOPUS:85114089445
SN - 0267-1379
VL - 37
SP - 532
EP - 538
JO - Current Opinion in Gastroenterology
JF - Current Opinion in Gastroenterology
IS - 5
ER -